StockData
BioXcel Therapeutics, Inc. logo

BioXcel Therapeutics, Inc. (BTAIQ) stock

BTAIQOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026Score 3/30
$0.03−0.00 (-13.49%)

Close on Oct 19, 2026Market cap $757.50KP/E –Yield –

BioXcel Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

BioXcel Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $21.56M, down 16.5% year over year. For fiscal 2025 it was $30.25M, down 0.6% from the year before. The highest annual figure on record is $91.24M in fiscal 2022.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$30.25M-0.6%
FY2024Dec 31, 2024$30.44M-63.9%
FY2023Dec 31, 2023$84.33M-7.6%
FY2022Dec 31, 2022$91.24M+73.1%
FY2021Dec 31, 2021$52.71M-9.1%
FY2020Dec 31, 2020$58.00M+124.8%
FY2019Dec 31, 2019$25.80M+77.2%
FY2018Dec 31, 2018$14.56M+441.2%
FY2017Dec 31, 2017$2.69M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$3.16M-69.1%
Q1 FY2026Mar 31, 2026$2.96M-35.1%
Q4 FY2025Dec 31, 2025$6.70M+13.6%
Q3 FY2025Sep 30, 2025$8.74M+71.3%
Q2 FY2025Jun 30, 2025$10.26M+27.7%
Q1 FY2025Mar 31, 2025$4.55M-60.1%
Q4 FY2024Dec 31, 2024$5.90M-40.6%
Q3 FY2024Sep 30, 2024$5.10M-74.0%
Q2 FY2024Jun 30, 2024$8.03M-70.2%
Q1 FY2024Mar 31, 2024$11.40M-59.0%
Q4 FY2023Dec 31, 2023$9.93M-69.4%
Q3 FY2023Sep 30, 2023$19.62M-11.1%
Q2 FY2023Jun 30, 2023$26.97M+50.6%
Q1 FY2023Mar 31, 2023$27.80M+49.8%
Q4 FY2022Dec 31, 2022$32.46M+159.2%
Q3 FY2022Sep 30, 2022$22.06M+84.9%
Q2 FY2022Jun 30, 2022$17.91M+32.5%
Q1 FY2022Mar 31, 2022$18.56M+25.9%
Q4 FY2021Dec 31, 2021$12.53M+9.9%
Q3 FY2021Sep 30, 2021$11.93M-26.9%
Q2 FY2021Jun 30, 2021$13.51M-24.6%
Q1 FY2021Mar 31, 2021$14.74M+19.2%
Q4 FY2020Dec 31, 2020$11.40M+75.5%
Q3 FY2020Sep 30, 2020$16.32M+129.1%
Q2 FY2020Jun 30, 2020$17.91M+175.2%
Q1 FY2020Mar 31, 2020$12.37M+118.0%
Q4 FY2019Dec 31, 2019$6.50M+7.9%
Q3 FY2019Sep 30, 2019$7.12M+86.4%
Q2 FY2019Jun 30, 2019$6.51M+265.3%
Q1 FY2019Mar 31, 2019$5.67M+93.1%
Q4 FY2018Dec 31, 2018$6.02M+322.0%
Q3 FY2018Sep 30, 2018$3.82M+517.3%
Q2 FY2018Jun 30, 2018$1.78M+449.7%
Q1 FY2018Mar 31, 2018$2.94M+815.3%
Q4 FY2017Dec 31, 2017$1.43M–
Q3 FY2017Sep 30, 2017$619.00K–
Q2 FY2017Jun 30, 2017$324.00K–
Q1 FY2017Mar 31, 2017$321.00K–

More BioXcel Therapeutics figures

See a number that looks wrong?